A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)

Trial Profile

A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Lusutrombopag (Primary)
  • Indications Thrombocytopenia
  • Focus Registrational; Therapeutic Use
  • Acronyms L-PLUS 2
  • Sponsors Shionogi
  • Most Recent Events

    • 25 Sep 2017 According to a Shionogi media release, based on the results from the L-PLUS1 and L-PLUS2 Phase 3 studies, Shionogi has initiated rolling submission of a New Drug Application to the FDA.
    • 25 Sep 2017 According to a Shionogi media release, data will be presented at future hepatology and hematology conferences later this year.
    • 25 Sep 2017 Results presented in a Shionogi media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top